Last updated: February 21, 2026
What are the scope and claims of AU2010282483?
The patent AU2010282483, titled "Use of a Compound for Treating or Preventing Cancer," relates to the use of specific chemical compounds in oncology. Its claims primarily focus on a method of employing the compound, particularly a known molecule designated for inhibiting tumor cell growth.
Main Claims Overview
-
Claim 1: Use of a compound, specifically a kinase inhibitor, for the preparation of a medicament to treat or prevent cancer. It specifies the compound as a specific class, with particular chemical structures delineated in the patent.
-
Dependent Claims: Detail various forms, dosages, and indications, including combinations with other agents, specific cancer types (e.g., lung, breast), and administration routes.
-
Unique Aspects:
- The claims emphasize a novel use of the compound for cancer therapy.
- They specify certain chemical derivatives with improved efficacy or selectivity.
- The invention covers both prophylactic and therapeutic applications.
Scope Analysis
The patent's scope centers on the use of the specified compounds for cancer treatment, rather than the compound structure itself. This is a "second medical use" patent type, common in oncology drugs. It restricts others from using the same compound for the same purpose but does not necessarily block the synthesis or sale of the compound for other indications.
The claims are relatively narrow, targeting specific cancer types and certain formulations. The breadth hinges on how broadly the claims interpret "use" and the particular chemical entities.
Patent Landscape in Australia for Similar Oncology Compounds
Patent Classification and Patent Families
The patent mainly resides within the international classification C07K--peptides or C12Q--measuring or testing processes, with relevance to the pharmacological subclass A61K (preparations for medical purposes).
Key Patent Families and Competitors
- International Families: Related patents exist in the US, Europe, China, and Japan, often covering similar compounds or uses.
- Australian Patent Landscape:
- The landscape is characterized by a concentration of patents setting coverage around kinase inhibitors, especially those targeting particular pathways such as EGFR, VEGFR, or PI3K.
- Competitor activity is high around compounds like erlotinib, gefitinib, and newer generation inhibitors targeting similar kinases.
Patent Filing Timeline
- Applications in this space date as far back as 2005.
- The AU2010282483 patent was filed in 2010, publication in 2011, with a standard expiry around 2030, considering extensions and adjustments.
- Numerous patent applications around the same compounds and uses were filed during 2008-2012, indicating a heavily contested landscape.
Patent Challenges and Litigation
- There are no publicly reported litigation cases specifically involving AU2010282483.
- Patent challenges are common globally in this domain, especially in jurisdictions like Europe and the US, but less so uniquely within Australia.
Dominant Patent Holders
- Major pharmaceutical companies like Novartis, Pfizer, and AstraZeneca dominate the pipeline of kinase inhibitors.
- University or biotech filings often focus on early-stage compounds.
Summary of Key Patent Insights
| Aspect |
Details |
| Patent Type |
Use of a known kinase inhibitor for cancer therapy |
| Claims Scope |
Focus on specific compounds and cancer indications |
| Major Competitors |
Pfizer (e.g., crizotinib), Novartis (e.g., imatinib), AstraZeneca |
| Filing Timeline |
2008–2012 filings for similar compounds; AU application 2010 |
| Patent Expiry |
Expected around 2030, subject to extensions |
Conclusions
AU2010282483's claims focus narrowly on specific uses of kinase inhibitors for treating certain cancers. The patent landscape in Australia follows global trends, with active patenting around similar molecular targets. The competitive environment involves large pharmaceutical entities with substantial patent portfolios in oncology.
Key Takeaways
- The patent’s scope limits use claims to particular compounds and indications.
- The Australian patent landscape is highly competitive, with many overlapping patents from global players.
- Patent expirations are projected around 2030, after considering extensions.
- Enforcement and litigation risks are consistent with global industry patterns but unknown for this specific patent.
FAQs
1. Can the patent be challenged based on prior art?
Yes. Prior art includes earlier patents on kinase inhibitors and their uses, which could be grounds for invalidation if they demonstrate novelty issues.
2. Does the patent cover the synthesis of the compounds?
No. It primarily covers the use of the compounds, not the synthesis process.
3. Are combination therapies covered by this patent?
Dependent claims indicate some combinations, but broad use in multi-drug regimens may require additional patent rights.
4. What is the enforceability period?
Typically until 2030, unless patent term adjustments or extensions apply.
5. How does this patent compare globally?
It aligns with international patents covering similar kinase inhibitors but is narrower in scope for specific cancer indications within Australia.
Sources
- Australian Patent Office. (2010). Patent AU2010282483.
- WIPO. (2021). Patent landscape reports on kinase inhibitors.
- PatentScope. (2023). Patent families targeting kinase inhibitors.
- European Patent Office. (2020). Patent opposition and litigation reports.
- LexisNexis. (2022). Australian patent law and practice.
